GILDKite, A Gilead CompanyRunning, no new patients
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory Mantle Cell Lymphoma · Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 25 (final count)
- Started
- Mar 18, 2024
- Main results expected
- Jul 2027
- Fully finished
- Jul 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
MCL Cohort: Objective Response Rate (ORR) Per Investigator Assessment
Measured over: Up to 24 months
ALL Cohort: Overall Complete Remission (OCR) Rate
Measured over: Up to 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06253663 · record last updated 2026-06-25 · checked 2026-11-09 15:47 UTC